SCHEMBL5543145

SCHEMBL5543145

CCOCCNC(=O)c1c(O)c2ncc(Cc3ccc(F)cc3)cc2[nH]c1=O

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.47
MAPK1 P28482 2/20 0.41
MEN1 O00255 5/20 0.40
KMT2A Q03164 5/20 0.40
KDM5A P29375 2/20 0.40
GSK3B P49841 1/20 0.39
USP2 O75604 1/20 0.39
KDM4E B2RXH2 3/20 0.38
RAB9A P51151 2/20 0.38
NPC1 O15118 1/20 0.38
PKM P14618 1/20 0.38
ALDH1A1 P00352 2/20 0.37
HSD17B10 Q99714 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
ALOX15 P16050 1/20 0.36
SERPINE1 P05121 1/20 0.36
RXFP1 Q9HBX9 2/20 0.36
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5540588 0.95 TDP1 (0.46) TDP1MEN1KMT2AKDM5AGSK3B
SCHEMBL16008690 0.94 TDP1 (0.47) TDP1MAPK1MEN1KMT2AKDM5A
SCHEMBL5546031 0.92 TDP1 (0.52) TDP1MAPK1MEN1KMT2AKDM5A
SCHEMBL5547281 0.91 TDP1 (0.45) TDP1MAPK1MEN1KMT2AKDM5A
SCHEMBL15163541 0.90 TDP1 (0.48) TDP1MAPK1MEN1KMT2AKDM5A
SCHEMBL5547382 0.89 TDP1 (0.47) TDP1MAPK1MEN1KMT2AKDM5A
SCHEMBL5540515 0.89 TDP1 (0.45) TDP1MAPK1MEN1KMT2AKDM5A
SCHEMBL5546471 0.87 TDP1 (0.48) TDP1MAPK1MEN1KMT2AKDM5A
SCHEMBL15163542 0.87 TDP1 (0.48) TDP1MAPK1MEN1KMT2AKDM5A
SCHEMBL4995843 0.87 TDP1 (0.45) TDP1MAPK1MEN1KMT2AKDM5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150225399-A1 HIV INTEGRASE INHIBITORS VIIV HEALTHCARE CO (US) 2015-08-13 US disclosed
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS SHIONOGI & CO., LTD. (JP) 2014-09-11 US disclosed
EP-1720856-B1 HIV INTEGRASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-08-14 EP disclosed
US-20070124152-A1 Hiv Integrase Inhibitors GLAXOSMITHKLINE LLC 2007-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS BCDIN3D, DUT, SAMHD1 TDP1 801/4885MAPK1 3455/4885MEN1 4802/4885
US-20150225399-A1 HIV INTEGRASE INHIBITORS ING2, API5, SAMHD1 TDP1 575/4885MAPK1 2267/4885MEN1 4837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.